Thomas Flaig, MD, leads collaborative research that could yield personalized therapy approach to muscle-invasive bladder cancer
Bladder cancer is the fourth most common cancer among adult men. In recent decades, however, research and treatment innovation for this disease have lagged. Thomas Flaig, MD, vice chancellor of research for CU Denver and CU Anschutz Medical Campus, recently presented findings from a 10-year-long effort to study bladder cancer biomarker development and treatment.
We spoke with Flaig on the recent abstract that he presented at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium in San Francisco.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
